

Figure 1.







Figure 3

4/10

Conversion from Inj. SLR to Paltusotine:
Change in IGF-1 from Baseline to Steady State at
Indicated Dose



Magnitude of Paltusotine Activity:
Change in IGF-1 from Steady State to 4 Weeks
After Withdrawal





Figure 4

SUBSTITUTE SHEET (RULE 26)


5/10



*Target=Mean trough concentration observed to suppress IGF-1 comparable to that of LA-SRLs in acromegaly patients

Figure 5

6/10

**Figure 6**





Figure 7A


Paltusotine lowered IGF-1 and maintained long-term IGF-1 control at levels previously achieved with injected SRLs



1. Baseline (screening) from Evolve studies while on injected SRL therapy.
 2. End of 4-week wash-out from paltusotine at end of Evolve study.
- ACROBAT Advance DATA-through August 31, 2021

Figure 7B

Paltusotine lowered IGF-1 levels and maintained long-term IGF-1 at levels previously achieved with injected SRLs



1. Baseline (screening) from Evolve/Edge studies while on injected SRL therapy.

2. End of 4-week wash-out from paltusotine at end of Evolve/Edge studies.
ACROBAT Advance DATA-through August 31, 2021

Figure 8A




Figure 8B